摘要
目的探讨保肺化纤方经转化生长因子(transforming growth factor,TGF)-β1/smad2/3、Wnt1/β-连环蛋白(catenin)信号通路减轻博来霉素(bleomycin,BLM)/PM2.5暴露诱导的特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)大鼠肺组织胶原沉积的作用机制。方法SD大鼠随机分为对照(Control)组、BLM+PM2.5(Model)组、保肺化纤方(BHF)组、吡非尼酮(pirfenidone,PFD)组、XAV-939组、BHF+PFD组、BHF+XAV-939组。采用一次性气管内雾化BLM法制备IPF大鼠模型,大气PM2.5实时浓缩全身暴露和给予相应药物干预。检测大鼠肺功能,观察肺组织病理和胶原沉积;采用免疫组化技术检测肺组织Ⅰ、Ⅳ型胶原(collagen,COL)、TGF-β1、smad2/3、β-catenin蛋白水平;采用qPCR技术检测肺组织TGF-β1、smad2/3、Wnt1、β-catenin mRNA水平。结果与Control组比较,Model组大鼠肺功能显著降低(P<0.01),肺组织可见大量炎症细胞浸润,肺泡壁断裂、增厚,胶原沉积等肺纤维化特征性病理改变,肺组织胶原容积分数(collagen volume fraction,CVF)、COLⅠ、COLⅣ蛋白及TGF-β1、smad2/3、β-catenin基因与蛋白表达均显著升高(P<0.01);与Model组比较,各治疗组均有效改善大鼠肺组织病理改变,显著降低肺组织CVF及COLⅠ、COLⅣ、TGF-β1、smad2/3、β-catenin蛋白表达水平(P<0.05,P<0.01),同时BHF组、BHF+PFD组、BHF+XAV-939组均能显著提高大鼠肺功能(P<0.05,P<0.01),明显下调肺组织TGF-β1、smad2/3、β-catenin基因表达水平(P<0.01);与PFD组比较,BHF+PFD组大鼠肺组织COLⅠ、TGF-β1蛋白及smad2、β-catenin基因表达均显著降低(P<0.05,P<0.01);与XAV-939组比较,BHF+XAV-939组smad3基因表达显著降低(P<0.01)。结论保肺化纤方可改善BLM/PM2.5诱导的IPF大鼠肺组织病理损伤,减少胶原沉积,提高肺功能,改善肺纤维化,其机制可能与下调TGF-β1/smad2/3、Wnt1/β-catenin通路有关。
Objective To investigate the mechanism of Baofei Huaxian Formula(保肺化纤方)via transforming growth factor(TGF)-β1/smad2/3 and Wnt1/β-catenin signaling pathway to reduce collagen deposition in lung tissue of rats with idiopathic pulmonary fibrosis(IPF)induced by bleomycin(BLM)/PM2.5.Methods SD rats were randomly divided into control(Control)group,BLM+PM2.5(Model)group,Baofei Huaxian Formula(BHF)group,pirfenidone(PFD)group,XAV-939 group,BHF+PFD group and BHF+XAV-939 group.The IPF rat model was prepared by disposable endotracheal nebulization bleomycin method,and atmospheric PM2.5 real-time concentrated animal exposure and corresponding drug intervention were given.The lung function of rats was detected,and lung histopathology and collagen deposition were observed.The protein levels of I andⅣcollagen(COL),TGF-β1,smad2/3 andβ-catenin in lung tissue were detected by immunohistochemistry.The mRNA levels of TGF-β1,smad2/3,Wnt1 andβ-catenin in lung tissue were detected by qPCR.Results Compared with those of the Control group,the lung function of rats in the Model group was significantly reduced(P<0.01),and the lung tissue was seen to be infiltrated by a large number of inflammatory cells,alveolar wall fracture,thickening,collagen deposition and other characteristic pathological changes of pulmonary fibrosis,and collagen volume fraction(CVF),gene and protein expressions of COLⅠ,COLⅣ,TGF-β1,smad2/3 andβ-catenin in lung tissue were significantly increased(P<0.01).Compared with the Model group,all treatment groups effectively improved the lung histopathological changes in rats,and significantly reduced CVF and the protein expression levels of COLⅠ,COLⅣ,TGF-β1,smad2/3 andβ-catenin in lung tissue(P<0.05,P<0.01),while the BHF group,BHF+PFD group and BHF+XAV-939 group significantly improved the lung function of rats(P<0.05,P<0.01)and significantly down-regulated the expression levels of TGF-β1,smad2/3 andβ-catenin genes in lung tissues(P<0.01).Compared with the PFD group,the expressions of COLⅠ,TGF-β1 protein and smad2 andβ-catenin genes in lung tissues of rats in the BHF+PFD group were significantly lower than those in the PFD group.The catenin gene expressions were significantly lower in the BHF+XAV-939 group compared with those in the PFD group(P<0.05,P<0.01)and smad3 gene expression was significantly lower in the BHF+XAV-939 group compared with that in the XAV-939 group(P<0.01).Conclusion The mechanism of Baofei Huaxian Formula to improve BLM/PM2.5-induced lung histopathological damage and lung function and reduce collagen deposition in IPF rats may be related to the down-regulation of TGF-β1/smad2/3 and Wnt1/β-catenin pathways.
作者
马宁怡
千孟丹
何慧慧
刘学芳
冯素香
刘素晓
林珊珊
李亚
MA Ningyi;QIAN Mengdan;HE Huihui;LIU Xuefang;FENG Suxiang;LIU Suxiao;LIN Shanshan;LI Ya(Henan University of Chinese Medicine,Zhengzhou 450046,Henan,China;Henan Key Laboratory of Chinese Medicine for Respiratory Disease,Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan&Education Ministry of P.R.,Zhengzhou 450046,Henan,China;Respiratory Pharmacological Laboratory of Chinese Medicine,Henan Key Laboratory of Chinese Medicine for the Prevention and Treatment of Respiratory Disease,The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,Henan,China)
出处
《辽宁中医杂志》
CAS
北大核心
2024年第9期191-195,I0005,共6页
Liaoning Journal of Traditional Chinese Medicine
基金
国家自然科学基金面上项目(81673775,82074403)
河南省中医药科学研究专项课题(20-21ZY1019)
河南省特色骨干学科中医学学科建设项目(STG-ZYXKY-2020014)
河南省科技厅重点研发与推广专项(科技攻关)(182102310102)。